AGICC (Academic GI Cancer Consortium) met in person for an Investigator’s Meeting during the recent GI-ASCO 2023 Symposium in San Francisco. This coming year the AGICC group will continue to explore GI oncology trials in partnership with pharmaceutical companies. 

Leading the group is Wells A. Messersmith, M.D. University of Colorado Cancer Center, Aurora, CO. Dr. Messersmith trained in internal medicine at Massachusetts General Hospital / Harvard Medical School and did his Medical Oncology / Drug Development Fellowship at Johns Hopkins, where he was on faculty as Assistant Professor in the GI Oncology and Drug Development programs. He joined the University of Colorado Cancer Center in August 2007 as the Director of Gastrointestinal Medical Oncology. He was appointed co-Leader of Developmental Therapeutics in 2010, and in 2014 became Division Head of Medical Oncology.

“The twice-yearly, in-person meetings for AGICC at the GI Symposium and ASCO Annual Meeting provide a great forum to discuss new clinical trial concepts from our investigators and collaborators in the pharma/biotech industry.  These meetings are also an excellent opportunity for our junior faculty and trainees to learn from some of the top clinician-scientists in the field.”  —Wells A. Messersmith M.D.

AGICC is a proud member of Criterium’s established consortia: Academic Thoracic Oncology Medical Investigators Consortium (ATOMIC), Academic Breast Cancer Consortium (ABRCC), Academic Urology Research Investigators Consortium (AURIC), Academic Myeloma Consortium (AMyC)